Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2020

View Archived Issues

Base editing gives temporary hearing fix

Nuclear quality control by chaperones

Sensorion reports preclinical findings on otoferlin gene therapy program

FDA clears IND application for first-in-class monoclonal anti-VISTA antibody, C-I8993

Interim phase I data for ONCOS-102 plus durvalumab in peritoneal malignancies

First-in-human data presented for ALT-P7 in advanced HER2-positive breast cancer

Modified peptides generate RA-specific CD4+ T cells with lytic properties against APCs

First connection between an ARSD gene variant and disease identified

Dana-Farber Cancer Institute and Voronoi patent DYRK1A inhibitors

U.K. researchers present BCL-6 inhibitors

Roche synthesizes new MGL inhibitors

Exon-intron fusions play role in osteosarcoma metastases

Merck & Co. describes new adenosine receptor antagonists

Novartis presents new PCSK9 inhibitors

New preclinical data presented on bispecific antibody ALG.APV-527 for solid tumors

AbbVie reports new phase IIa data on ABBV-3373 in moderate to severe rheumatoid arthritis

Cleave begins phase I study of CB-5339 in relapsed/refractory AML and MDS

BioCryst reports data from Zika virus study of galidesivir in primate model

Phase III trial of INP-104 for acute migraine meets primary objectives

Phase I/IIa trial studies Turnstone's TBio-6517 in solid tumors

Actuate Therapeutics begins pediatric phase I study of 9-ING-41 for refractory malignancies

Domain Therapeutics' biased PAR2 inhibitors show antiarthritic effects

Regeneron initiates first clinical trial of REGN-COV2 antibody cocktail for COVID-19

Dosing begins in phase I study of BBP-418 for limb girdle muscular dystrophy type 2i

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...